Ashworth A - Search Results

1

ATR Is a Therapeutic Target in Synovial Sarcoma.

Jones SE, Fleuren EDG, Frankum J, Konde A, Williamson CT, Krastev DB, Pemberton HN, Campbell J, Gulati A, Elliott R, Menon M, Selfe JL, Brough R, Pettitt SJ, Niedzwiedz W, van der Graaf WTA, Shipley J, Ashworth A, Lord CJ. Jones SE, et al. Among authors: ashworth a. Cancer Res. 2017 Dec 15;77(24):7014-7026. doi: 10.1158/0008-5472.CAN-17-2056. Epub 2017 Oct 16. Cancer Res. 2017. PMID: 29038346 Free PMC article.

2

Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1.

Spicer J, Rayter S, Young N, Elliott R, Ashworth A, Smith D. Spicer J, et al. Among authors: ashworth a. Oncogene. 2003 Jul 24;22(30):4752-6. doi: 10.1038/sj.onc.1206669. Oncogene. 2003. PMID: 12879020

3

Phenotypic effects of heterozygosity for a BRCA2 mutation.

Warren M, Lord CJ, Masabanda J, Griffin D, Ashworth A. Warren M, et al. Among authors: ashworth a. Hum Mol Genet. 2003 Oct 15;12(20):2645-56. doi: 10.1093/hmg/ddg277. Epub 2003 Aug 19. Hum Mol Genet. 2003. PMID: 12928478

4

DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells.

Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A. Gudmundsdottir K, et al. Among authors: ashworth a. EMBO Rep. 2004 Oct;5(10):989-93. doi: 10.1038/sj.embor.7400255. Epub 2004 Sep 10. EMBO Rep. 2004. PMID: 15359272 Free PMC article.

5

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Farmer H, et al. Among authors: ashworth a. Nature. 2005 Apr 14;434(7035):917-21. doi: 10.1038/nature03445. Nature. 2005. PMID: 15829967 Free article.

6

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.

McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. McCabe N, et al. Among authors: ashworth a. Cancer Biol Ther. 2005 Sep;4(9):934-6. doi: 10.4161/cbt.4.9.2141. Epub 2005 Sep 1. Cancer Biol Ther. 2005. PMID: 16251802 Free article.

7

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.

Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, Hartley JA, Hochhauser D. Friedmann BJ, et al. Among authors: ashworth a. Mol Cancer Ther. 2006 Feb;5(2):209-18. doi: 10.1158/1535-7163.MCT-05-0239. Mol Cancer Ther. 2006. PMID: 16505093 Free article.

8

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A. Tutt AN, et al. Among authors: ashworth a. Cold Spring Harb Symp Quant Biol. 2005;70:139-48. doi: 10.1101/sqb.2005.70.012. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869747

9

Targeting the double-strand DNA break repair pathway as a therapeutic strategy.

Lord CJ, Garrett MD, Ashworth A. Lord CJ, et al. Among authors: ashworth a. Clin Cancer Res. 2006 Aug 1;12(15):4463-8. doi: 10.1158/1078-0432.CCR-06-1269. Clin Cancer Res. 2006. PMID: 16899589 Review.

10

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. McCabe N, et al. Among authors: ashworth a. Cancer Res. 2006 Aug 15;66(16):8109-15. doi: 10.1158/0008-5472.CAN-06-0140. Cancer Res. 2006. PMID: 16912188

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

843 results

Search Page

Filters